CD80
ENSG00000121594
Target class
Surface antigen
Chromosome
3
Approved drugs
2
Clinical candidates (approved and in development)
3
- Approved drugs
- 2
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- No
- Target name
- CD80
- Gene name
- CD80 molecule
- Gene symbol
- CD80
- Protein name
- T-lymphocyte activation antigen CD80 (Activation B7-1 antigen) (BB1) (CTLA-4 counter-receptor B7.1) (B7) (CD antigen CD80)
- B7.1
- B7-1
- CD28LG
- CD28LG1
- Gene biotype
- Protein coding
- Gene family
- CD molecules|V-set domain containing|C2-set domain containing|B7 family
- Target class
- Surface antigen
- Target type
- Human gene
- Tissues expressed in
- 3
- Highest tissue expression
- 74.27
- Tissue specificity (Gini)
- 0.93
- Tissue specificity (tau)
- 0.996
- KEGG gene identifiers
- hsa:941
- Protein interaction confidence
- 0.83598
- Protein interaction partners
- 99
- R-HSA-1257604
- R-HSA-2219530
- R-HSA-389356
- R-HSA-389357
- R-HSA-389359
- R-HSA-389513
- R-HSA-6783783
- R-HSA-6811558
- End position
- 119569324
- Start position
- 119523898
- Chromosome
- 3
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein.
- PubMed 2794510
- PubMed 38467718
- Tissue specificity (tau)
- 0.996319
- Expression inequality (Gini)
- 0.929502
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 74.27
- Lung
- 3.77
- Spleen
- 3.3
- Thyroid
- 0.82
- Small Intestine - Terminal Ileum
- 0.77
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes74.27
- Lung3.77
- Spleen3.3
- Thyroid0.82
- Small Intestine - Terminal Ileum0.77
- Artery - Aorta0.51
- Artery - Coronary0.39
- Kidney - Medulla0.26
- Minor Salivary Gland0.24
- Adipose - Visceral (Omentum)0.23
- Testis0.21
- Adipose - Subcutaneous0.2
- Colon - Transverse0.2
- Nerve - Tibial0.19
- Cervix - Endocervix0.19
- Breast - Mammary Tissue0.19
- Uterus0.17
- Prostate0.17
- Adrenal Gland0.17
- Pituitary0.15
- Pancreas0.15
- Whole Blood0.14
- Artery - Tibial0.14
- Brain - Spinal cord (cervical c-1)0.12
- Esophagus - Mucosa0.12
And 29 more, listed on the interactive page.
- GO:0002710
- GO:0042110
- GO:0050731
- GO:0050862
- GO:0005886
- GO:0009986
- GO:0098636
- GO:0005515
- GO:0048018
Related records
Trials (492)
- A Belatacept Compassionate Use Study for Patients With a Kidney Transplant
- A Clinical Research of CAR T Cells Targeting CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma
- A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
- A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- A Clinical Study Exploring Universal CAR-T Cell in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
- A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1- and EpCAM-positive Solid Tumors
- A Clinical Study on the Safety and Efficacy of CAR-T Therapy for the TM4SF1-positive Tumors of Digestive System
- A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
- A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory Acute Myeloid Leukemia
- A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia
- A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata
- A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
- A Dose-ranging Pediatric Study of an Adjuvanted Pandemic Influenza Vaccine
- A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
- A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
- A Phase 3 Study of Abatacept in Chinese Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
- A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
- A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
- A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
Drugs (3)
- Abatacept T-lymphocyte activation antigen CD80 inhibitor
- Belatacept T-lymphocyte activation antigen CD80 inhibitor
- Galiximab T-lymphocyte activation antigen CD80 inhibitor